Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data

  • By

  • Xin Zhao

  • Shujing Wu

  • Zhen Wang

  • Luning Zhou

  • Peng Zhang

  • Huajie Xu

  • Mengmeng Yu

  • Zhiyong Qi

  • Lili Xu

  • Neng Dai

  • Hongbo Yang

  • Yingnan Bai

  • Bing Fan

  • Juying Qian

  • Hongyi Wu

  • Junbo Ge

  • January 9, 2026

Share

  • 1

    Acute coronary syndromes (ACS) are a leading cause of death globally, necessitating effective lipid-lowering therapies (LLT) for management.

  • 2

    In China, new insurance policies since January 2022 have made PCSK9 inhibitors more accessible, potentially altering LLT patterns in ACS patients.

  • 3

    The study utilized a large, prospective database to analyze LLT trends and LDL-C goal attainment in ACS patients before and after the policy change.

  • 4

    Despite guidelines recommending intensive LLT, many post-ACS patients in China still fail to meet LDL-C targets, highlighting ongoing treatment gaps.

  • 5

    The research aims to provide insights into LLT practices and outcomes for ACS patients, informing future lipid-lowering strategies in China.

Original Source(s)

Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data

  • by Xin Zhao, Shujing Wu, Zhen Wang, Luning Zhou, Peng Zhang, Huajie Xu, Mengmeng Yu, Zhiyong Qi, Lili Xu, Neng Dai, Hongbo Yang, Yingnan Bai, Bing Fan, Juying Qian, Hongyi Wu, Junbo Ge

  • January 9, 2026

Related Content

Procedural volume and outcomes of Impella support in cardiogenic shock

Correction: Variations in Predictive Value of Serum Uric Acid for Major Adverse Cardiovascular Events by Gender in Acute Coronary Syndrome Patients: A Retrospective Cohort Analysis

Effects of Angiotensin Receptor-Neprilysin Inhibitors on Lung Cancer Patients with Hypertension Receiving Immune Checkpoint Inhibitor Therapy